Utah Medical Products(US:UTMD) ZACKS·2025-10-29 18:31Core Viewpoint - Utah Medical Products, Inc. (UTMD) reported a disappointing third quarter for 2025, with significant declines in earnings and revenue, attributed to unexpected order cancellations and a challenging operating environment [1][2][5]. Financial Performance - Earnings per share (EPS) for Q3 2025 was 82 cents, down 19.9% from $1.025 in the same quarter last year [1]. - Revenue decreased by 1.9% to $9.8 million from $10 million year-over-year [2]. - Net income fell by 26.2% to $2.6 million from $3.6 million [2]. Key Business Metrics - Gross profit declined 3.4% year-over-year to $5.6 million, with gross margin dropping to 57.1% from 58% [3]. - Operating income decreased by 21.9% to $2.6 million, resulting in an operating margin of 26.6%, down from 33.4% [3]. - Adjusted EBITDA fell 15.9% to $4.2 million, with the adjusted EBITDA margin contracting to 42.5% from 49.6% [4]. Management Commentary - Management cited unexpected cancellations or delays from two non-U.S. distributors, leading to a revenue loss of $0.6 million and a $0.4 million bad debt provision [5]. - The cancellation from a China distributor may indicate the end of a long-term business relationship [5]. - Sales from former major OEM customer PendoTECH dropped to $0.01 million from $0.3 million year-over-year, but management believes this decline has nearly bottomed out [6]. Factors Influencing Results - Manufacturing costs increased due to U.S. tariffs, impacting the cost of goods sold by $0.08 million in Q3 [7]. - Gross margins were further affected by under-absorption of fixed overheads due to lower sales volumes [7]. - Litigation expenses were high at $0.38 million, though down from $0.43 million a year earlier [8]. Revenue Breakdown - Domestic U.S. sales rose 3% year-over-year, driven by a 7.7% increase in direct device sales and a 16.5% gain in Filshie product sales [9]. - International sales declined by 8.5%, significantly impacted by a 21.7% drop in constant currency OUS sales [9]. Guidance - Management now expects full-year 2025 revenue to decline approximately 7% year-over-year, revised from an earlier estimate of a 5% drop [11]. - Adjusted EBITDA for the full year is projected to be in the range of $17 to $18 million [11]. Other Developments - During the quarter, UTMD repurchased 11,729 shares for $0.7 million, totaling 130,984 shares worth $7.4 million year-to-date [12]. - Dividends paid during the quarter amounted to $1 million, representing 38% of quarterly net income [12]. - Since the end of 2023, UTMD has spent $34.6 million on share repurchases and dividends, with a minimal decrease of $8.6 million in cash and investments, indicating strong cash generation capacity [12].